Conditions: Dyslipidemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 191
Healthy volunteers: no

Brief summary:
This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.

Detailed description:

Arms:
arm 1: MK1903 arm 2: Placebo to MK1903

Interventions: intervention 1: MK1903 intervention 2: Comparator: Placebo
Intervention descriptions: intervention 1: Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period. intervention 2: Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.

Protocol document: